Free tool
FAERS Monitor: Zegerid
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021849 or its brand name (Zegerid, Omeprazole, Sodium Bicarbonate). Reports on generic versions are filed under their own applications.
Reports
2,739
Serious
1,742
64% of reports
Hospitalization
536
Death reported
167
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- chronic kidney disease788
- acute kidney injury456
- renal failure431
- end stage renal disease212
- drug ineffective200
- renal injury195
- nausea167
- gastrooesophageal reflux disease156
- pain135
- headache131
- fatigue126
- diarrhoea109
- tubulointerstitial nephritis101
- dyspnoea90
- anxiety87
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 7 |
| 2006 | 14 |
| 2007 | 26 |
| 2008 | 62 |
| 2009 | 86 |
| 2010 | 119 |
| 2011 | 145 |
| 2012 | 142 |
| 2013 | 102 |
| 2014 | 97 |
| 2015 | 148 |
| 2016 | 150 |
| 2017 | 172 |
| 2018 | 301 |
| 2019 | 513 |
| 2020 | 187 |
| 2021 | 153 |
| 2022 | 101 |
| 2023 | 45 |
| 2024 | 72 |
| 2025 | 58 |
| 2026 | 39 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,420 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| end stage renal diseaseSignal | 212 | 90.3 | 79.3 | 18,432 |
| chronic kidney diseaseSignal | 788 | 80.5 | 75.8 | 61,341 |
| renal injurySignal | 195 | 50.7 | 44.3 | 9,407 |
| tubulointerstitial nephritisSignal | 101 | 41.6 | 34.3 | 3,944 |
| renal failureSignal | 431 | 25.0 | 22.9 | 9,937 |
| acute kidney injurySignal | 456 | 22.9 | 21.1 | 9,591 |
| gastrooesophageal reflux diseaseSignal | 156 | 14.9 | 12.8 | 2,014 |
| anxietySignal | 87 | 2.3 | 1.9 | 67 |
| pain | 135 | 1.7 | 1.4 | 38 |
| nausea | 167 | 1.6 | 1.4 | 41 |
| headache | 131 | 1.6 | 1.4 | 30 |
| diarrhoea | 109 | 1.3 | 1.1 | 7 |
| fatigue | 126 | 1.2 | 1.0 | 6 |
| dyspnoea | 90 | 1.2 | 1.0 | 3 |
| drug ineffective | 200 | 1.2 | 1.0 | 5 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.